MarginsXMarginsX
Home › Markets › Health Care › CRMD

CorMedix Inc. (CRMD)

CRMD trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$4.82
+3.43% on the day
Market cap
$383.4M
Small cap
Revenue · 2025
$311.7M
+617.0% on 2024
Net income · 2025
$163.1M
52.3% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1410098/000121390026023889/0001213900-26-023889-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerCRMD on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO yearNot reported by the screener
SEC CIK0001410098
SEC industry codePharmaceutical Preparations
Incorporated inDE

Financials · 2025

LineValue
Revenue$311.7M
Net income$163.1M
Operating income$150.1M
Net margin52.3%
Operating margin48.2%
Revenue growth+617.0%
Cash$144.8M
Total assets$826.1M
P/E (computed)2.4×
P/S (computed)1.2×

Warning signs

Cash runway
Cash-flow positive
$355.1M cash at September 30, 2026
Share count, 1 year
+1.0%
2025-11-10 to 2026-11-09 · +45.1% over 3 years
Going-concern doubt
No
10-Q filed November 12, 2026
Insider net buying, 12 months
-$2.4M
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-11-12
Cash and burn$355.1M cash; operating cash flow $78.2M a quarter.Report 2026-09-30
Shares outstanding79,537,626 (2026-11-09); 78,789,045 a year earlier; 54,812,042 three years earlier.Cover page 2026-11-09
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 0 424B5 takedownsNone on EDGAR
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorCBIZ CPAs P.C., Morristown, New Jersey, United States; changed auditors 2 times in 24 months8-K 4.01 2026-07-01
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $276K, sold $2.6M on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
$54.5M-$14.7M$89.7M$355.1MNo debt tags$412.5M10-Q 2026-11-12
Q2 2026
2026-06-30
$101.9M$26.0M$86.2M$256.7MNo debt tags$462.2M10-Q 2026-08-13
Q1 2026
2026-03-31
$127.4M$38.6M$42.4M$178.1MNo debt tags$400.1M10-Q 2026-05-14
Q4 2025
2025-12-31
$128.6M$14.0M$94.5M$144.8M$145K$311.7M10-K 2026-03-05
Q3 2025
2025-09-30
$104.3M$108.6M$30.9M$48.5M$144.5M$214.3M10-Q 2025-11-12
Q2 2025
2025-06-30
$39.7M$19.8M$30.0M$159.3MNo debt tags$121.5M10-Q 2025-08-07
Q1 2025
2025-03-31
$39.1M$20.6M$19.7M$66.3MNo debt tags$82.6M10-Q 2025-05-06
Q4 2024
2024-12-31
$31.2M$13.5M-$5.6M$40.7MNo debt tags$43.5M10-K 2026-03-05

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document
REGISTRATION STATEMENT
S-3ASR2025-10-07
Latest annual report
ANNUAL REPORT
10-K2026-03-05
Latest quarterly / interim10-Q2026-11-12
Latest current report
CURRENT REPORT
8-K2026-11-16
Latest proxy
CURRENT REPORT
DEFA14A2026-11-16

Source: SEC EDGAR submissions feed, 1,004 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-12.4%
1 month-36.9%
3 months-42.8%
Year to date-59.9%
1 year-58.4%
From 52-week high-63.4%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
RLMDRelmada Therapeutics Inc.$3.61-14.25%$385.2M
CTNMContineum Therapeutics Inc.$9.67-1.93%$379.7M
PBYIPuma Biotechnology Inc$7.34-5.53%$379.5M
IRDOpus Genetics Inc.$4.04+1.51%$390.5M
PEPGPepGen Inc.$4.19-3.90%$395.0M
SPRYARS Pharmaceuticals Inc.$3.59-7.71%$360.9M
PRTAProthena Corporation plc$7.97-2.33%$409.3M
ASPEAspen Neuroscience Inc.$12.23-2.86%$355.6M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier